Coronary Heart Disease
Conditions
Interventions
Control group:Standard dual antiplatelet therapy only
Intervention group:Loading dose of Shexiang Tongxin Dripping Pills combined with dual antiplatelet therapy
Sponsors
Shanghai Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients (40 to 80 years of age) with unstable angina pectoris (unstable angina was diagnosed when there were new or worsening symptoms of ischemia or changing symptom pattern, and ischemic electrocardiograph changes with normal biomarkers) undergoing elective PCI were randomized to receive STDP plus DAPT or DAPT alone.
Exclusion criteria
Exclusion criteria: 1. Allergies or intolerance to clopidogrel/aspirin; 2. The use of P2Y12 receptor antagonist or immunosuppressive agent within the past six months; 3. A recent history of active bleeding, or infection, or acquired immunodeficiency syndrome; 4. Acute ST-segment elevation myocardial infarction undergoing emergency PCI; 5. Malignant tumors, severe liver or kidney disease, abnormal blood coagulation, or low platelet count (< 100,000/L); 6. A history of major surgery within 6 months; 7. Heart failure (New York Heart Association Classification III or above); 8. Participation in any other trial within the past one month. All patients signed informed consent forms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PMP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory cytokines;hsTnI;CKMB;MACEs; | — |
Countries
China
Contacts
Public ContactMeng Shu
Shanghai Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed